FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235- 0104							
Estimated average burden								
hours per	0.5							

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FERRARI RICHARD M	2. Date of Requiring (Month/Date 09/30/20	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol Pulmonx Corp [LUNG]						
(Last) (First) (Middle) C/O PULMONX CORPORATION 700 CHESAPEAKE DRIVE			4. Relationship of Reportir Issuer (Check all applicable) X Director	ng Person(s) to 10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year) 09/30/2020			
(Street) REDWOOD CITY CA 94063 (City) (State) (Zip)	_		Officer (give title below)			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Beneficially Owned									
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock		10,832		See Footnote ⁽¹⁾					
(e			e Securities Benefici Ints, options, conver						
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security		Direct (D) or Indirect (I) (Instr. 5)		
Series A-1 Preferred Stock	(2)	(2)	Common Stock	26,266	(2)		I	See Footnote ⁽¹⁾	
Series B-1 Preferred Stock	(2)	(2)	Common Stock	675,227	(2)		I	See Footnote ⁽¹⁾	
Series C-1 Preferred Stock	(2)	(2)	Common Stock	327,560	(2)		I	See Footnote ⁽¹⁾	
Series D-1 Preferred Stock	(2)	(2)	Common Stock	126,603	(2)		I	See Footnote ⁽¹⁾	
Series E-1 Preferred Stock	(2)	(2)	Common Stock	65,833	(2)		I	See Footnote ⁽¹⁾	
Series G-1 Preferred Stock	(2)	(2)	Common Stock	3,030	(2)		D		

Explanation of Responses:

- 1. The shares are directly held by De Novo Ventures III Liquidating Trust ("De Novo"). The Reporting Person, along with Fred Dozier and Joseph Mandato, and Jay Watkins are the trustees of De Novo and exercise shared voting and dispositive control over the shares held by De Novo.
- 2. Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date.

Remarks:

/s/ Mark Weeks, Attorney-In-Fact

10/02/2020

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.